...
首页> 外文期刊>Clinical Research in Cardiology >Pulmonary hypertension: current diagnosis and treatment
【24h】

Pulmonary hypertension: current diagnosis and treatment

机译:肺动脉高压:当前的诊断和治疗

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Pulmonary hypertension (PH) is a devastating disease that – if untreated – is characterized by a poor prognosis. According to the current classification (Venice, 2003), pulmonary arterial hypertension (PAH) is distinguished from other forms of PH. Recent advances in drug therapy have led to a dramatic improvement of medical care particularly in patients with PAH. Hence, early establishment of the diagnosis appears increasingly important. This review article gives an overview on the definition, classification, pathophysiology, and clinical presentation of various forms of PH. Furthermore, it summarizes the recommended diagnostic work-up and the current treatment options particularly in PAH, with special emphasis on prostanoids, endothelin receptor antagonists (ERAs), and phosphopdiesterase type 5 (PDE5) inhibitors such as sildenafil. Finally, novel developments are being discussed which currently represent an exciting field of research.
机译:肺动脉高压(PH)是一种破坏性疾病,如果不加以治疗,其预后不良。根据当前分类(Venice,2003年),肺动脉高压(PAH)与其他形式的PH有所区别。药物治疗的最新进展已导致医疗服务的显着改善,尤其是在PAH患者中。因此,早期建立诊断显得越来越重要。这篇综述文章概述了各种形式的PH的定义,分类,病理生理和临床表现。此外,它总结了推荐的诊断方法和当前的治疗方案,尤其是在PAH中,特别强调了类前列腺素,内皮素受体拮抗剂(ERAs)和5型磷酸二酯酶(PDE5)抑制剂,如西地那非。最后,正在讨论的新颖发展目前代表着令人兴奋的研究领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号